Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Ready
Primary summary from verified readiness
- Confidence
- 63% · fresh
- Computed at
- 2026-08-20T10:55:58.390052+00:00
- Claimed
- 90
- Reported
- 80
- Verified
- 69
- Gap
- +21
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed leads verified
Evidence strength Critical
Decision
What the current evidence supports
Human editorial judgment · 2026-08-20
Proceed with caution
- Why
- The efficacy evidence is unusually strong and mechanistically first-in-class — two 12-week randomized placebo-controlled phase 3 studies enrolling 273 adults supported approval, on top of a phase 2 showing MWT sleep latency +23.5 min (2 mg BID) versus -1.2 min on placebo — but the product is approved-and-unavailable: DEA scheduling is unresolved, no official label is published in DailyMed or openFDA as of 2026-08-10, and 60%/58%/11% AE rates mean the risk conversation is real rather than nominal.
- Next
- Re-check the DEA scheduling outcome and wait for the published U.S. label to appear in DailyMed/openFDA before treating Orzeyful as prescribable; when it lands, gate any patient-facing claim on the NT1-only indication and on monitoring for insomnia, urinary frequency and CPK elevation.
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 8
- Tier 1
- 0
- Tier 2
- 2
- Tier 3
- 6
- Supports
- 4
- Contradicts
- 3
- Context
- 1
- Latest observed
- 2026-08-05
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
- 2026-08-10 Reading moved from ready to ready.